Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma (#9105)

• ClinicalTrials.gov Identifier: NCT01065272
• Recruitment Status: Completed
• First Posted: February 9, 2010
• Last Update Posted: August 10, 2016
• Sponsor: Hamad Medical Corporation
• Information provided by (Responsible Party): Hamad Medical Corporation

Study Description

Brief Summary:

The investigators hypothesized that oral Dexamethasone in addition to nebulized Salbutamol will improve the Bronchiolitis Clinical Severity Score,duration of treatment in the short stay unit,need for hospitalization and readmissions to the pediatric emergency in a subgroup of patients diagnosed as Bronchiolitis with either eczema and or a parental or sibling history of Asthma.

Two groups randomized will be given Nebulized Ventolin plus either oral Dexamethasone or placebo for 5 days.

Bronchiolitis severity score plus vital signs will be recorded regularly until patient is fit for discharge.

Patients will be discharged on Ventolin inhaler and to complete the five days course of oral Dexamethasone Patients will be followed up for 7 days post discharge by telephone.

Condition or disease	Intervention/treatment	Phase
Bronchiolitis	Drug: Dexamethasone; Drug: Placebo	Phase 1

Detailed Description:

This is a prospective, randomized, double blinded controlled study. It will be conducted in the main Pediatric Emergency Centre in Qatar(Al- Saad),during the period of Jan 2010 - April 2012.

The study has been approval by the Institution Research Board. The sample size will be 200 patients.100 patients in each arm.

Patients triaged as moderate to severe bronchiolitis will be evaluated and eligible patients are admitted to short stay unit and managed as usual. History and full physical examination will be done by the attending physician and the nurse will check 02 sat., respiratory rate and pulse rate.

The Bronchiolitis clinical severity score will be assessed and then guardians of eligible patients will be approached explaining the purpose and treatment modalities.

Patients will be included after obtaining a verbal and written consent. A CXR and an RSV test will be done for all study patients upon recruitment. The attending physician will complete the data collection sheet A computer generated randomization code will be prepared by the statistician. A pharmacist will prepare the study medications and the placebo. Patients will be randomized to either one of the two treatments:- Ventolin-Dexamethasone group: Oral Dexamethasone 1mg/kg will be given for the first day and then 0.6mg/kg for the next 4 days in addition to the Ventolin nebulizations.

Ventolin-Placebo group: Oral Placebo with a volume equivalent to that of Dexamethasone will be given for the first day and then for the next 4 days in addition to the Ventolin nebulizations.

Nebulized Ventolin 0.5ml in 2 ml Normal Saline will also be given at 0, 30, 60, 120 and 180 minutes and then every 2hours.

Bronchiolitis severity score and O2 saturation will be recorded at enrollment, then after 4,6 and 12hours then every 12 hourly until discharged.

To give additional Ventolin nebulization will be decided clinically as per the discretion of the treating physician and will be recorded.

Nebulized epinephrine will not be used except if the patient is severely distressed. Nebulized Epinephrine 0.5 mg/kg (max 5mg/dose) mixed in 3ml normal saline will be allowed for severely distressed patients as an add on therapy given on PRN basis..

Additional interventions such as Oxygen therapy, Intravenous fluids and PRN nebulized Epinephrine will be recorded as additional therapies.

Patients fit for discharge will have their nebulization stopped & date, time documented.

Physician will discharge patients based on clinical grounds as not needing supplemental oxygen,minimal or no chest recessions,minimal wheezing or crackles and feeding adequately Patients will be sent home on Ventolin inhaler 2 puffs q 4 hours for 48 hours Then 2 puffs every 4 hours when needed plus the study medication syrup to complete 5days course.

Follow up for one-week post discharge by a phone call daily will be conducted and patients will be assessed in PEC when needed.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Dexamethasone Versus Placebo in the Treatment of Viral Bronchiolitis in Patients With Either Eczema and or Parental or Sibling History of Asthma.A Randomized Controlled Trial.
• Study Start Date: February 2010
• Actual Primary Completion Date: August 2012
• Actual Study Completion Date: August 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Ventolin - Dexamethasone group; Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.	Drug: Dexamethasone; 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge. 1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days; Other Name: Steroids
Placebo Comparator: Ventolin - Placebo group; Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.	Drug: Placebo; 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge. 1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days; Other Name: normal saline plus cherry flavour

Outcome Measures

Primary Outcome Measures :

1. Patients diagnosed as bronchiolitis were discharged at 12 hours for each group [ Time Frame: 12 hours ]

Secondary Outcome Measures :

1. Patients diagnosed as bronchiolitis were discharged at 18, 24 , 36 and 48 hours for each group [ Time Frame: 48 hours ]

Eligibility Criteria

• Ages Eligible for Study: 4 Weeks to 18 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Infant's ≥ 4weeks and ≤ 18 month.
• First time wheezers.
• Bronchiolitis clinical severity score ≥ 4.
• History of eczema in the patient.
• Parenteral history of asthma
• Sibling history of asthma

Exclusion Criteria:

• Prematurity (Gestational age 34 weeks or less).
• Previous history of wheezing episode.
• Use of steroids within the last 48 hours.

• Critically ill patients with one or more of the following:

  • Obtunded consciousness,
  • Progressive respiratory failure requiring PICU admission.
  • History of apnea.
  • Oxygen saturation less than 85%.
• Chronic lung disease of prematurity.
• Cystic fibrosis.
• Congenital heart disease.
• Immunodeficiency.
• Exposure to Varicella within 21 days before enrollment.

Contacts and Locations

Locations

Qatar

Hamad Medical Corporation, Pediatric Emergency Center,Alsaad.

Doha, Qatar, 3050

Sponsors and Collaborators

Hamad Medical Corporation

Investigators

• Principal Investigator: Khalid M Al-Ansari, FRCPC,FAAP; Hamad Medical Corporation, Weill Cornell Medical College, Doha-Qatar

More Information

• Responsible Party: Hamad Medical Corporation
• ClinicalTrials.gov Identifier: NCT01065272
• Other Study ID Numbers: #9105/09; #9105/09 ( Other Identifier: Hamad Medical Corporation )
• First Posted: February 9, 2010
• Last Update Posted: August 10, 2016
• Last Verified: September 2012

Keywords provided by Hamad Medical Corporation:

Dexamethasone; Bronchiolitis

Additional relevant MeSH terms:

Bronchiolitis; Bronchitis; Respiratory Tract Infections; Infections; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Dexamethasone; Anti-Inflammatory Agents; Antiemetics; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents